NEW YORK (Reuters Health)—A large Swedish study1 provides reassuring data on the risk of cancer in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF) inhibitors or with tocilizumab, abatacept or rituximab. Overall, the risk of malignant neoplasms did not differ between patients treated with a first anti-TNF drug; a second anti-TNF drug; tocilizumab,…
Search results for: cancer
FDA Approves First Biosimilar for the Treatment of Cancer
Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment…
IBD Treatments Don’t Seem to Raise Extracolonic Cancer Risk
NEW YORK (Reuters Health)—Immunosuppressants and anti-TNF drugs do not appear to increase the risk of extracolonic cancers in patients with inflammatory bowel disease (IBD), researchers from Spain report. IBD patients face an increased risk of colon cancer, and some studies have suggested there might be an increased risk of extracolonic cancer. Dr. Maria Chaparro from…
The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…
Complex Treatment: Cancer, Immunotherapy & Rheumatic Disease
Some cancer patients taking immune checkpoint inhibitors experience immune-related adverse events. Laura C. Cappelli, MD, MHS, says rheumatologists are natural partners with oncologists to treat this patient population…
Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Introduction: Major advances in the past two decades have enhanced our understanding of the complex interactions between the immune system and cancer cells and their environment. Genetic and epigenetic alterations in tumor cells result in the expression of diverse antigens that can elicit an immune response, primarily mediated by T cells. Immune responses are regulated…
Cancer Risk for Patients with Juvenile Idiopathic Arthritis Taking TNF Inhibitors
WASHINGTON, D.C.—Juvenile idiopathic arthritis (JIA) patients taking TNF inhibitors don’t develop new cancers at a higher rate than JIA patients who don’t take TNF inhibitors, according to the largest study so far conducted to study the possible link. The findings were reported at the 2016 ACR/ARHP Annual Meeting in an abstract session that also included…
Distinct Autoantigens Found in Patients with Scleroderma & Coincident Cancer
Recent research examined the relationship between patients with scleroderma who are anti-CTP antibody negative and cancer. Combing two complementary technologies, PhIP-Seq and PLATO-BC, researchers identified the POLR3 complex in cancer-associated scleroderma…
FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling
The makers of FX006, a steroid injection for treating pain in patients with knee osteoarthritis, have submitted a new drug application to the FDA…
From the Expert: Insight into the Intersection of Cancer & Autoimmunity
Research by Dr. Anthony Rosen, MD, and colleagues found a link between cancer and scleroderma, suggesting the immune system may edit cancer cells. In an interview with The Rheumatologist, Dr. Rosen explores the meaning of this finding and its potential…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 80
- Next Page »